Company overview
Lucid Scientific offers RESIPHER, an innovative system for continuous, non-invasive monitoring of oxygen consumption in cell culture plates. The platform uses proprietary optical oxygen sensors that are 10 times smaller and more sensitive than competitors, streaming real-time data via a web app for applications like cell growth, dose response, and cell line development. RESIPHER integrates into a sterilized lid for standard 96-well plates, enabling monitoring for up to four weeks.
Lucid Scientific is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include cell culture sensors, oxygen consumption monitoring, resipher, non-invasive cell analysis, 96-well plate sensors.
Products and technologies associated with Lucid Scientific include Cell Culture — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://lucidscientific.com
- Markets served
- United States & Americas
- Keywords
- cell culture sensors, oxygen consumption monitoring, resipher, non-invasive cell analysis, 96-well plate sensors
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What is RESIPHER and how does it work?
- RESIPHER is Lucid Scientific's flagship technology providing continuous, non-invasive oxygen consumption measurement in cell culture plates using highly sensitive optical sensors integrated into a sterilized lid for standard 96-well plates, with data streamed to a web app.
- What are the key advantages of Lucid's sensors?
- Lucid's proprietary oxygen sensors are 10 times smaller and 10 times more sensitive than competitors, offering precise real-time measurements for cell growth, dose response, and cell line development.
- What cell culture formats does RESIPHER support?
- RESIPHER fits directly on most standard 96-well cell culture plates and supports continuous monitoring for up to four weeks.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
